Merck & Co., Inc. Launches Global Patient Registry Supporting Expanded Commitment To Real-World Outcomes Research In Type 2 Diabetes

Published: Jun 13, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the launch of a global registry to evaluate the experiences and outcomes of approximately 20,000 patients with type 2 diabetes in real-world settings over three years. The registry is part of Merck’s new global research initiative evaluating outcomes of patients with type 2 diabetes in everyday clinical practice. The research initiative and the new registry reflect Merck’s broader commitment to generate real-world evidence to help advance diabetes care.

Help employers find you! Check out all the jobs and post your resume.

Back to news